dilantin

Phenytoin, known widely by its brand name Dilantin, is one of those foundational antiepileptic drugs (AEDs) that every neurologist and even many general practitioners have a complicated relationship with. It’s been around since the 1930s—discovered by Putnam and Merritt—and for decades was the go-to for controlling tonic-clonic and complex partial seizures. We’re talking about a hydantoin derivative, a sodium channel blocker that’s dirt cheap and widely available, but oh, the pharmacokinetics… they’re a nightmare. Nonlinear, saturable metabolism, extensive protein binding, and a therapeutic range so narrow you’re constantly dancing on the edge of toxicity. I still remember my first month on the neurology service as a resident, spending half my time adjusting Dilantin doses based on levels that made no sense, while the other half was spent managing gingival hyperplasia in long-term users.

## 1. Introduction: What is Dilantin? Its Role in Modern Medicine

So, what is Dilantin? Chemically, it’s phenytoin, a hydantoin compound that acts as a voltage-gated sodium channel blocker. It’s primarily used for seizure control—specifically, for preventing and treating tonic-clonic and partial seizures. It’s also used off-label for neuropathic pain and certain cardiac arrhythmias, though that’s less common now with newer agents. Despite its age, Dilantin remains a workhorse in status epilepticus protocols and in settings where cost is a major factor. But its role has definitely evolved; it’s no longer first-line for many due to its side effect profile and drug interactions, but in resource-limited settings or for certain patient phenotypes, it’s irreplaceable.

## 2. Key Components and Bioavailability of Dilantin

Dilantin is available in several formulations: immediate-release capsules, extended-release (Dilantin Kapseals), oral suspension, and injectable. The active ingredient is phenytoin, obviously, but the formulation matters immensely. The extended-release capsules are designed to slow absorption and minimize peak-trough fluctuations—critical given its nonlinear kinetics. The oral suspension? That one’s tricky; it’s not bioequivalent to the capsules due to differences in particle size and dissolution rates. I’ve seen patients switched from capsules to suspension without dose adjustment end up toxic or subtherapeutic within days. Bioavailability is nearly complete for the oral forms, but it’s formulation-dependent. The injectable form uses propylene glycol as a solvent, which can cause hypotension and cardiac issues if infused too quickly—hence the max rate of 50 mg/min in adults.

## 3. Mechanism of Action of Dilantin: Scientific Substantiation

How does Dilantin work? It stabilizes neuronal membranes by blocking voltage-gated sodium channels in their inactive state. This prevents high-frequency repetitive firing—the kind you see in seizure activity—without affecting normal neuronal transmission. It’s use-dependent, meaning it preferentially binds to channels that are firing rapidly. There’s also some evidence it modulates calcium influx and potentiates GABAergic inhibition, but the sodium channel blockade is the main event. Think of it like putting a speed bump on a hyperactive neural highway; it doesn’t stop all traffic, just the cars going too fast. This mechanism is why it’s so effective in focal onset seizures and generalized tonic-clonic types.

## 4. Indications for Use: What is Dilantin Effective For?

Dilantin for Seizure Disorders

This is its bread and butter. FDA-approved for tonic-clonic and complex partial seizures, and for prevention and treatment of seizures following neurosurgery. It’s also used in status epilepticus IV, though fosphenytoin (a prodrug) is preferred now due to better tolerability.

Dilantin for Neuropathic Pain

Off-label, but supported by older studies—particularly for trigeminal neuralgia. It’s fallen out of favor compared to gabapentinoids and TCAs, but I’ve had patients who’ve failed everything else respond to phenytoin.

Dilantin for Cardiac Arrhythmias

Rarely used now, but it’s a class Ib antiarrhythmic. We’re talking digitalis-induced arrhythmias mainly, and even that’s historical.

## 5. Instructions for Use: Dosage and Course of Administration

Dosing is notoriously tricky. For adults, loading doses are often used in acute settings—15-20 mg/kg IV, not exceeding 50 mg/min. Maintenance dosing is weight-based, usually 5-7 mg/kg/day, but because of saturable metabolism (zero-order kinetics at higher doses), small increases can lead to disproportionate rises in serum levels. You have to monitor levels closely; therapeutic range is 10-20 mcg/mL. Here’s a rough guide:

IndicationInitial Adult DoseTitrationTarget Level
Seizure prophylaxis5 mg/kg/dayIncrease by 30 mg q2-3 weeks10-20 mcg/mL
Status epilepticus15-20 mg/kg IVMaintenance 5 mg/kg/day15-25 mcg/mL (acute)

Always take with food to minimize GI upset, and be consistent with formulation—don’t switch between capsule and suspension without rechecking levels.

## 6. Contraindications and Drug Interactions of Dilantin

Contraindications include hypersensitivity to phenytoin or other hydantoins, sinus bradycardia, SA block, and Adams-Stokes syndrome. Relative contraindications: hepatic impairment, porphyria. The drug interactions are a nightmare—Dilantin induces CYP2C9, CYP2C19, and CYP3A4, so it lowers levels of oral contraceptives, warfarin, many antidepressants, and even other AEDs like carbamazepine. Meanwhile, drugs that inhibit these enzymes (like fluoxetine, isoniazid) can skyrocket phenytoin levels. I had a patient on stable doses for years whose levels shot up to 35 mcg/mL after starting fluconazole for a fungal infection—ended up with nystagmus and ataxia until we figured it out.

## 7. Clinical Studies and Evidence Base for Dilantin

The evidence for Dilantin is old but robust. The VA Cooperative Study in the 1980s established its efficacy in partial and generalized seizures. More recent studies compare it unfavorably to newer agents in terms of tolerability, but it’s still in all the guidelines. For status epilepticus, the landmark study by Treiman et al. showed IV phenytoin was effective, though now levetiracetam is often preferred due to better safety profile. The Cochrane review from 2019 still places phenytoin as a viable option, especially where cost is a barrier.

## 8. Comparing Dilantin with Similar Products and Choosing a Quality Product

Compared to levetiracetam, Dilantin has more drug interactions and chronic side effects (gingival hyperplasia, hirsutism, osteomalacia) but is cheaper. Versus valproate, it’s less teratogenic but harder to dose. When choosing, consider formulation—branded Dilantin Kapseals have more predictable release than some generics. Look for manufacturers with good bioavailability data, and stick with one once you find a reliable source. In my experience, the Pfizer brand is still the gold standard, though many generics are fine if you monitor levels.

## 9. Frequently Asked Questions (FAQ) about Dilantin

For seizure control, it often takes 2-3 weeks to reach steady state after initiation or dose change. Long-term use requires periodic level checks—every 6-12 months if stable.

Can Dilantin be combined with other AEDs?

Yes, but carefully. It induces metabolism of carbamazepine and valproate can displace it from protein binding, increasing free fraction. Always monitor levels.

Is Dilantin safe during pregnancy?

Pregnancy Category D. It’s associated with fetal hydantoin syndrome (craniofacial abnormalities, limb defects). If used, levels must be monitored frequently—pregnancy increases clearance.

What are the signs of Dilantin toxicity?

Nystagmus, ataxia, slurred speech, drowsiness. Severe toxicity can cause coma, hypotension. Chronic toxicity includes cerebellar atrophy, peripheral neuropathy.

## 10. Conclusion: Validity of Dilantin Use in Clinical Practice

Despite its drawbacks, Dilantin remains a valid, cost-effective option for seizure control in selected patients. Its narrow therapeutic index and interaction profile demand careful management, but when used judiciously, it can be highly effective.


I’ll never forget Mrs. G, 72, with post-stroke epilepsy, who’d been on Dilantin for 15 years. Her previous doc had her on 400 mg/day, levels always around 18. She moved, came to my clinic with complaints of unsteady gait and “thickening gums.” Checked her level—24. We backed her down to 350 mg, but her gait didn’t improve much. Got a brain MRI—cerebellar atrophy. Classic chronic phenytoin toxicity. We switched her to levetiracetam, but she had psychiatric side effects, then to lacosamide, which worked. But here’s the thing—she missed the predictability of Dilantin. “At least I knew it was working,” she said. That’s the trade-off. Another case: young guy, 28, new-onset seizures, no insurance. Started on generic phenytoin, 300 mg/day. Levels subtherapeutic at 6. Upped to 400 mg—level 22. We ended up keeping him at 350 mg, level 14. He’s been seizure-free 3 years now, can’t afford anything else. These are the realities. Our team argued for months about phasing out Dilantin entirely, but the cost-benefit for some patients just isn’t black and white. We had one patient whose levels would swing wildly on the same dose—turned out she was taking her capsules with calcium supplements, which chelate phenytoin. Moved dosing to 2 hours apart, problem solved. Little things. After 20 years, I still learn something new with this drug. Follow-ups? Mrs. G’s gait stabilized off phenytoin, but she had two breakthrough seizures on lacosamide before we got the dose right. She now says she’s “more clear-headed,” but it was a rough transition. The young guy? Still on phenytoin, still seizure-free, still can’t afford MRI follow-ups. He sent a card last Christmas—“Thanks for not giving up on me.” That’s why we still use it.